Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-11-12
1995-03-21
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514338, 514341, 514407, 546146, 546147, 546174, 546175, 5483644, 5483647, 5483694, 5483697, 5483704, 5483661, A61K 31415
Patent
active
053995651
ABSTRACT:
Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described.
REFERENCES:
patent: 3312550 (1967-04-01), Stewart et al.
patent: 3957814 (1976-05-01), Moller et al.
patent: 4081596 (1978-03-01), Moller et al.
patent: 4902708 (1990-02-01), Kim
patent: 5153191 (1992-10-01), Woodruff
patent: 5300514 (1994-04-01), Brown et al.
Neitzel et al., Liebigs Ann. Chem., 1907-1912 (1980).
Howbert et al., Multiple Cholecystokinin Receptors-Progress Toward CNS Therapeutic Targets Abstract, Harlow, England, Sep. 20-22, 1990.
Hodgkiss, et al. Multiple Cholecystokinin Receptors-Progress Toward CNS Therapeutic Targets Abstract, Harlow, England, Sep. 20-22, 1990.
Lucaites et al., Soc. Neurosci. Abstr. 16:82, 1990.
Howbert et al., Soc. Neurosci. Abstr. 16:82, 1990.
Howbert, Joint Great Lakes-Central Regional Meeting of American Chemical Society, Indianapolis, Ind., May 29-31, 1991.
Howbert, Invited Lectures, McGill University (Nov. 28, 1990), Univ. Sherbrook (Nov. 29, 1990), Indiana Univ. School of Med. (Dec. 4, 1990; Dec. 6, 1990), Johns Hopkins Univ. (Jan. 29, 1991) Howbert, Society for Drug Research, London, England, Mar. 21, 1991.
Rasmussen, Methods of Evaluation for Psychopharmacology, Butler Universty, Indianapols, Ind., Apr. 23, 1993.
Howbert et al., LY288513, an Antagonist of Brain Cholecystokinin Receptors, American College of Neurospychopharmacology, San Juan, Puerto Rico, Dec. 14-18, 1992.
Palmour et al., Anxiogenic Effects of CCK Agonists in a Non-human Primate Model: Central or Peripheral?, International Symposium, Chatham, Mass., May 19-22, 1993.
Howbert et al., Differential Ability of a Pyrazolidinone Type A CCK Receptor Antagonist to Block the Gastric Inhibitory and Pyloric Contractile Actions of CCK, International Symposium, Chatham, Mass., May 19-22, 1993.
Howbert et al., CCK.sub.B Receptors Tonically Modulate a 10 Dopaminergic Neurons: Neurochemical Evaluation of LY288513, Annual Society for Neuroscience Meeting, Washington, D.C., Nov. 7-12, 1993.
Tollefson, CCK Antagonist and Other Related Neuropeptides as Anxiolytics, First International Congress on Hormones, Brain and Neuropsychopharmacology, Sep. 1993.
Schmidt et al., Behavioral and Electrophysiological Characterization of the New Cholecystokinin (CCK)-B Antagonist LY288513, Society for Neuroscience Meeting, Washington, D.C., Nov. 1993.
Hughes et al., Development of a Class of Selective Cholecystokinin Type B Receptor Antagonists having Potent Anxiolytic Activity, Proc. Natl., Acad. Sci. USA, 87:6728-6732, 1990.
Bock, Development of Non-Peptide Cholecystokinin Type B Receptor Antagonists, Drugs of the Future, 16(7):631-640, 1991.
Staley et al., CCK Antagonists Interact with CCK-B Receptors on Human Small Cell Lung Cancer Cells, Peptides, 11(5):1033-6, Sep.-Oct., 1990.
Greenwood et al., Mechanisms by Which CCK-8 Stimulates Gallbladder and Colonic Motility in the Ferret, American Gastroenterological Association/American Association for the Study of Liver Diseases, Abstr., Boston, Mass., May 16-19, 1993.
Greenwood et al., CCK-8 Contracts the Gallbladder and Colon Through Different Mechanisms in the Ferret, New York Academy of Sciences, Jul. 15, 1993.
Singh et al., The Antagonism of Benzodiazepine Withdrawal Effects by the Selective Cholecystokinin .sub.B B Receptor Antagonist CI-988, Br. J. Pharmacol., 105, 8-100, 1992.
Rasmussen et al., The CCK-B Antagonist LY288513 Blocks Diazepam-Withdrawal-Induced Increases in Auditory Startle Response, Abstr., New York Academy of Sciences, Jul. 15, 1993.
Rasmussen, CCK, Schizophrenia, and Anxiety: CCK-B Antagonists Inhibit the Activity of Brain Dopamine Neurons, New York Academy of Sciences Jul. 15, 1993.
Rasmussen et al., Electrophysiological Effects of Diphenylpyrazolidinone CCK-B and CCK-A Antagonists on Midbrain Dopamine Neurons, The Journal of Pharmacology and Experimental Therapeutics, (accepted Sep. 1992).
Iyengar, CCK.sub.B Receptors Tonically Modulate A10 Dopaminergic Neurons: Neurochemical Evaluation of LY288513, International Symposium, Cape Cod, May 19-22, 1993.
Boyce et al., Modulatory Role for CCK-B Antagonists in Parkinson's Disease, Clinical Neuropharmacology, 13:339-347, 1990.
Rasmussen, Quinazolinone CCK-B Antagonists Decrease the Number of Spontaneously Active Dopamine Neurons, Society for Neuroscience Convention, Anaheim, Calif., Oct. 26, 1992.
Rasmussen et al., Cholecystokinin (CCK) and Schizophrenia: The Selective CCK.sub.B Antagonist LY262691 Decreases Midbrain Dopamine Unit Activity, European Journal of Pharmacology, 209:135-138, 1991.
Palmour et al., Anxiogenic and Cardiovascular Effects of CCK-4 in Monkeys are Blocked by the CCK-B Antagonist LY262691, Society for Neuroscience Meeting, 1991 Annual Meeting, New Orleans, La., Aug. 1991.
Howbert et al., A Novel Series of Non-Peptide CCK and Gastrin Antagonists: Medicinal Chemistry and Electrophysiological Demonstration of Antagonism, CCK symposium, Harlow, England, Oxford University Press 29-37, 1992.
Totterdell et al., Cholecystokinin-Immunoreactive Boutons in Synaptic Contact with Hippocampal Pyramidal Neurons that Project to the Nucleus Accumbens, Neuroscience, 19:181-192, 1986.
Rasmussen et al., Electrophysiological Effects of Diphenylpyrazolidinone Cholecystokinin-B and Cholecystokinin-A Antagonists on Midbrain Dopamine Neurons, Journal of Pharmacology and Experimental Therapeutics, 264:480-488, 1993 (Accepted Sep. 8, 1992).
Rasmussen et al., Inihbition of A9 and A10 Dopamine Cells by the Cholecystokinin-B Antagonist LY262691: Mediation Through Feedback Pathways From Forebrain Sites, Synapse, 15:95-103, 1993.
Rasmussen et al., The CCK-B Antagonist LY288513 Blocks Effects of Diazepam Withdrawal on Auditory Startle, NeuroReport, 5:154-156, 1993.
Yu, et al., Quinazolinone CCK-B antagonists decrease the number of spontaneously active dopamine neurons, Soc. for Neurosc. Abstr. (1992)278.
Greenwood Beverley
Helton David R.
Howbert J. Jeffry
Mitan Steven J.
Rasmussen Kurt
Covington Raymond
Eli Lilly and Company
Ivy C. Warren
Vorndran-Jones MaCharri R.
LandOfFree
Pyrazolidinone CCK and gastrin antagonists and pharmaceutical fo does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolidinone CCK and gastrin antagonists and pharmaceutical fo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolidinone CCK and gastrin antagonists and pharmaceutical fo will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1149098